Literature DB >> 1371128

Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo.

D K Bishop1, W Li.   

Abstract

Modified limiting dilution analysis techniques were used to evaluate the effects of the immunosuppressants cyclosporin A (CsA) and FK506 on alloantigen-induced T cell activation in vivo. Treatment of sponge matrix allograft recipients with either CsA or FK506 inhibited lymphocytic infiltration of the allograft, a process thought to be dependent on local lymphokine production. In addition, both immunosuppressants markedly reduced the absolute number of lymphocytes recovered from the draining lymph nodes (LN) and prevented CTL activation in the LN. However, Ag-primed helper T lymphocytes (HTL) were present in the draining LN of sponge allograft recipients treated with CsA, but not in recipients treated with FK506. T cell depletion experiments were performed to determine the phenotype of primed HTL in the LN of untreated and CsA-treated sponge allograft recipients. In untreated sponge allograft recipients, CD4+ and CD8+ Ag-primed HTL were present in the draining LN in equivalent numbers. In contrast, the majority of primed HTL in the LN of CsA-treated sponge allograft recipients were CD8+, rather than CD4+ T cells. These observations indicate that CsA and FK506 exert distinct in vivo effects at the level of HTL priming, and CD4+ and CD8+ HTL exhibit differential sensitivity to CsA in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371128

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation.

Authors:  S Miyamoto; B Safer
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

2.  FK506 augments activation-induced programmed cell death of T lymphocytes in vivo.

Authors:  K Migita; K Eguchi; Y Kawabe; T Tsukada; A Mizokami; S Nagataki
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

3.  Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity.

Authors:  G P Geba; W Ptak; P W Askenase
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 4.  Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

Authors:  Ron Ram; Rainer Storb
Journal:  Leuk Lymphoma       Date:  2013-01-24

5.  Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.

Authors:  H M Ockenfels; G Nussbaum; T Schultewolter; P M Burger; M Goos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  Failure of FK 506 to suppress the T cell-mediated immunity of mice to Listeria monocytogenes.

Authors:  J A Wagner; M Kretschmar; T Nichterlein; H Hof; B Quade
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

7.  Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.

Authors:  A Cesano; S Visonneau; L Cioé; S C Clark; D Santoli
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

8.  Prevention of antigen-induced bronchial hyperreactivity and airway inflammation in sensitized guinea-pigs by tacrolimus.

Authors:  J R Lapa e Silva; C Ruffié; J Lefort; M A Nahori; B B Vargaftig; M Pretolani
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

9.  A direct comparison of rejection by CD8 and CD4 T cells in a transgenic model of allotransplantation.

Authors:  Paige M Porrett; Major K Lee; Moh Moh Lian; Jing Wang; Andrew J Caton; Shaoping Deng; James F Markmann; Daniel J Moore
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.